Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

NCT06169215 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

70

Enrollment

NIH

Sponsor class

Conditions

Multiple Myeloma

Interventions

PROCEDURE: Biospecimen Collection
PROCEDURE: Bone Marrow Aspiration
PROCEDURE: Bone Marrow Biopsy
DRUG: Bortezomib
PROCEDURE: Computed Tomography
DRUG: Daratumumab and Recombinant Human Hyaluronidase
DRUG: Dexamethasone
DRUG: Lenalidomide
PROCEDURE: Magnetic Resonance Imaging
PROCEDURE: Positron Emission Tomography
DRUG: Selinexor

Sponsor

National Cancer Institute (NCI)